Antisense IGF and antisense IGF-IR therapy of malignancy.
Wang
H
H
Shanghai International Joint Cancer Institute, Second Military Medical University, Shanghai, P. R. China.
Liu
Y
Y
Wei
L
L
Guo
Y
Y
D000818:Animals; D015316:Genetic Therapy / Q000379:methods; D005822:Genetic Vectors; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000235:genetics* / Q000378:metabolism; D007335:Insulin-Like Growth Factor II / Q000378:metabolism; D020319:Oligodeoxyribonucleotides, Antisense; D016372:RNA, Antisense; D017526:Receptor, IGF Type 1 / Q000235:genetics*; D017527:Receptor, IGF Type 2 / Q000378:metabolism
D020319:Oligodeoxyribonucleotides, Antisense; D016372:RNA, Antisense; D017527:Receptor, IGF Type 2; D007334:Insulin-Like Growth Factor I; D007335:Insulin-Like Growth Factor II; D017526:Receptor, IGF Type 1